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Methods: We undertook a 52-week Phase III study in 220 bvFTD patients randomized to compare hydromethylthionine at
200 mg/day and 8 mg/day (intended as a control). The principal outcomes were change on the Addenbrookes Cognitive Exam-
ination – Revised (ACE-R), the Functional Activities Questionnaire (FAQ), and whole brain volume. Secondary outcomes
included Modified Clinical Global Impression of Change (Modified-CGIC). A population pharmacokinetic exposure-response
analysis was undertaken in 175 of the patients with available blood samples and outcome data using a discriminatory plasma
assay for the parent drug.
Results: There were no significant differences between the two doses as randomized. There were steep concentration-
response relationships for plasma levels in the range 0.3–0.6 ng/ml at the 8 mg/day dose on clinical and MRI outcomes. There
were significant exposure-dependent differences at 8 mg/day for FAQ, Modified-CGIC, and whole brain atrophy comparing
patients with plasma levels greater than 0.346 ng/ml with having minimal drug exposure. The exposure-response is biphasic
with worse outcomes at the high concentrations produced by 200 mg/day.
Conclusions: Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain
atrophy at the 8 mg/day dose in bvFTD as recently reported in AD. Treatment responses in bvFTD are predicted to be
maximal at doses in the range 20–60 mg/day. A confirmatory placebo-controlled trial is now planned.
Keywords: Behavioral variant frontotemporal dementia, clinical trials, hydromethylthionine, leucomethylthioninium, tau
protein, TDP-43
INTRODUCTION
Behavioral variant frontotemporal dementia
(bvFTD) is a clinical syndrome characterized by
progressive deterioration of personality, social
comportment, and cognition [1]. Although a rare
disorder, bvFTD is the second most common
cause of dementia under age 65; there are also a
significant number of cases in older people [2, 3].
The diagnosis of bvFTD is primarily clinical, with
insidious onset and progressive deterioration, the
core symptoms being disinhibition, apathy, lack of
empathy, compulsions, hyperorality, and impairment
of executive function. There are also patients who
exhibit similar symptoms, but who do not suffer
from a neurodegenerative condition [4, 5]. This
phenocopy is characterized by preservation of func-
tional ability [6], absence of a genetic abnormality
[3], and normal imaging [5]. Patients with bvFTD
decline significantly more rapidly on cognitive and
functional measures than patients with AD [7], with
mean survival from symptom onset approximately
8 years [8]. For a given level of severity, prevalence
of significant burden in carers is much higher
in bvFTD compared with AD [9], and patients
with neuropathologically confirmed bvFTD have
a significantly higher prevalence of criminal and
socially inappropriate behavior compared with AD
[10]. Because the typical age of onset is earlier than
for AD [11, 12], the condition has a direct impact
on working life and on household income. At 2016
US costs, bvFTD was found to reduce income from
$75,000–$99,000 before diagnosis to $50,000 [13].
There are no treatments licensed for any form
of FTD. There is no reliable evidence of benefit
for acetylcholinesterase inhibitors [14, 15] and some
suggestion that they may make FTD symptoms worse
[16, 17]. Memantine is better tolerated but is also
ineffective [18, 19]. There have been numerous small
studies of other drugs targeting the behavioral symp-
toms, with some evidence of a small beneficial effect
of trazadone on Neuropsychiatric Inventory (NPI)
score [20]. However, the NPI is unsuitable as an out-
come measure because the increasing passivity that
accompanies disease progression is scored as a better
outcome [21].
bvFTD and AD are both members of a class of pro-
gressive neurodegenerative disorders characterized
by pathological aggregation and prion-like spread of
otherwise normal proteins [22]. The largest consecu-
tive bvFTD autopsy study published to date showed
there is high confidence of a clinical diagnosis of
bvFTD; characteristic pathology is present in 94%
of cases, with 84% having pathological aggregation
of tau protein (27%) or transactive response DNA
binding protein 43 (TDP-43; 57%) [23]. There is
increasing recognition of the importance of tau aggre-
gation pathology as a substrate of clinical dementia
and as a target for therapy in AD [24], and by
implication in prion-like neurodegenerative disorders
involving other proteins such as TDP-43.
The most advanced late-stage program target-
ing pathological protein aggregation currently in
development is based on leuco-methylthioninium
bis(hydromethanesulphonate) (LMTM) [25]. LMTM
has recently been assigned the International
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Nonproprietary Name (INN) ‘hydromethylthionine’,
recognizing it as chemically and pharmacologi-
cally distinct from methylthioninium chloride (MTC,
methylene blue). The methylthioninium (MT) moi-
ety can exist in oxidized (MT+) and reduced (LMT)
forms. LMTM is a stabilized salt of LMT which has
better brain uptake and tolerability than the oxidized
MT+ form [26]. We have retained the LMTM abbre-
viation in contexts that require technical discussion
of the distinctive properties of LMT, but otherwise we
now use the INN more generally. We have reported
recently that LMT rather than MT+ is the active
species blocking tau aggregation in vitro and that it
acts at a tau:LMT molar ratio of 1 : 0.1 [27]. Its site
of action is within the proteolytically stable core tau
unit of the tau aggregates found in both bvFTD and
AD [28–30]. LMT blocks aggregation of the core tau
unit in cell-based assays [25] and reduces tau aggre-
gation pathology and associated behavioral deficits in
a tau transgenic mouse model of bvFTD at clinically
relevant doses [31]. There was increased clearance
of pathological tau via enhancement of autophagy at
the 10–20 nM concentration range in a mouse model
of bvFTD [32] and reversal of resistance of filamen-
tous tau to proteases [25, 33]. The MT moiety inhibits
aggregation of TDP-43 in cell models with an EC50
of 0.05M [34], although not in a TDP-43 mouse
model at a dose unlikely to have been sufficient for
MTC activity [35].
The MT moiety has a range of other properties
that affect cellular metabolism. It has been known
for some time that it enhances mitochondrial activ-
ity at low concentrations (10–100 nM) [36, 37] by
acting as a supplementary electron carrier in the elec-
tron transfer chain. This has been confirmed recently
in an AD-like tau transgenic mouse model in which
hydromethylthionine was found to increase Complex
IV activity in the brain at clinically relevant doses
[38]. It is able to induce mitochondrial biogenesis and
to activate Nrf2-mediated oxidative stress response
elements in vivo [39]. Other potentially beneficial
activities include neuroprotective effects in the brain
by inhibiting microglial activation and increasing
autophagy [40]. Therefore, in addition to its actions
on tau and TDP-43 aggregation, the MT moiety has
complementary actions which address many of the
pathways currently advocated as having potential for
the treatment of neurodegenerative diseases [41–43].
We have previously reported the results of two
Phase III trials using hydromethylthionine in AD
[44, 45]. Both trials were designed as dose com-
parison studies, comparing doses in the range
150–250 mg/day with a low dose (8 mg/day) that was
intended as a control to mask the urinary discoloration
that occurs variably when urine from patients taking
any form of MT is exposed to air [46]. The expec-
tation was that this low dose would have no effect
on brain structure or function, an expectation based
on the results of an earlier placebo-controlled dose-
finding Phase II trial using MTC which identified
138 mg/day as the minimum effective dose in AD
[47], and early comparative Phase I pharmacokinetic
studies showing similar plasma levels of total MT
measured after acid extraction of samples [48]. How-
ever, we have found that this assay is dominated by
an acid-labile inactive conjugate in plasma which is
not distinguished from the active parent form of the
drug following acid extraction.
We have developed a sensitive assay which can
measure parent drug levels in plasma and which has
been found to be reliable and accurate in preclinical
and Phase I studies. Using this assay in a population
pharmacokinetic (PK) study in 1,162 patients partici-
pating in the AD trials, we recently reported [49] that
there is a steep concentration-response relationship
on all clinical and brain magnetic resonance imaging
(MRI) outcomes in patients receiving the 8 mg/day
dose. Hydromethylthionine therefore has pharmaco-
logical activity on brain structure and function in the
majority of AD patients at this dose. We also found
that there is a predicted plateau in response at theoret-
ical doses above 16 mg/day, consistent with the lack
of dose-response at much higher doses in AD [49].
The design of the present Phase III study in bvFTD
(TRx-237-007) was based on the same underlying
premise as the AD trials, comparing a high dose of
hydromethylthionine (200 mg/day given in divided
doses twice daily) with a low dose (8 mg/day given
in divided doses twice daily). We now report that, as in
AD, there was no overall difference on any endpoint
between these two doses in bvFTD. We also report
the results of the embedded population PK analysis of
clinical and MRI biomarker outcomes similar to that
recently reported in AD [49], to determine how drug
exposure is related to treatment response in bvFTD.
MATERIALS AND METHODS
Study design and participants, randomization
and masking, and outcomes
The study was designed as a 52-week Phase III,
randomized, controlled, double-blind, parallel-group
trial conducted between May 2013 and February
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2016 at 70 sites in Canada, United States, Aus-
tralia, Asia, and Europe. Eligible patients had to
be younger than 80 years of age with a diagno-
sis of bvFTD according to criteria revised by the
International bvFTD Criteria Consortium [1, 50],
with Mini-Mental Status Examination (MMSE) score
greater than or equal to 20 at screening. In order to
limit inclusion of bvFTD phenocopy cases, there was
an additional requirement that patients had to meet
the criterion of having definite brain atrophy in frontal
and/or temporal lobes scoring 2 or more on a scale
previously developed by Kipps et al. [51]. Concomi-
tant use of acetylcholinesterase inhibitors (AChEIs)
or memantine (or both) was permitted provided this
was at a stable dose for at least 18 weeks before
randomization to minimize any potential early symp-
tomatic effects of these treatments. Concomitant use
of antidepressant, antipsychotic (except clozapine or
olanzapine), and sedative medications was also per-
mitted at stable doses where clinically feasible. Each
patient had one or more study partners participate
with them in the trial as informants. Patients were
excluded from the study if they had a significant CNS
disorder other than bvFTD. A detailed list of inclu-
sion and exclusion criteria is in the protocol provided
in the Supplementary Material.
Patients were randomly assigned to receive
hydromethylthionine 100 mg twice a day or
hydromethylthionine 4 mg twice a day (n = 220). The
randomization was stratified according to geograph-
ical region (three levels: North America, Europe,
Asia/Australia). The randomization file and investi-
gational medicinal product kit list were unavailable
to personnel involved in conducting the study prior
to final analysis after database lock. Study partici-
pants, their informant(s), and all assessors remained
masked to treatment assignment throughout the study,
and safety assessors were not permitted to be involved
in efficacy assessments.
The two doses were provided in identical blis-
ter packages as visually identical oral tablets to
be taken for up to 52 weeks. The primary out-
come was the Addenbrookes Cognitive Examination
– Revised (ACE-R) [52]. The Functional Activ-
ities Questionnaire (FAQ) [53] and reduction in
progression of whole brain atrophy were alterna-
tive co-primary outcomes. Other outcomes included:
Modified Alzheimer’s Disease Cooperative Study –
Clinical Global Impression of Change (Modified-
CGIC) [21] determined by a third independent rater;
Frontotemporal Dementia Rating Scale (FRS) [54];
MMSE (from MMSE items incorporated into ACE-
R); Addenbrookes Cognitive Examination – III (a
revised version of ACE-R which excludes MMSE
items subject to copyright restrictions [55]); change in
brain volume measured by MRI in frontal and tempo-
ral lobes (FTV) and lateral ventricles (LVV); and the
effect of hydromethylthionine in patients with known
genetic mutations associated with bvFTD. Blood was
collected prospectively for the purpose of population
PK analyses.
MRI scans were obtained at screening and weeks
16, 32, and 52. The acquisition protocol was standard-
ized across sites and all data were centrally collected,
quality-controlled, and analyzed by the imaging
core laboratory (Bioclinica). MRI data included a
3D sagittal T1-weighted sequence (using parameters
compatible with the ADNI protocol) which was used
for all volumetric analyses. For data passing quality-
control, baseline volume was automatically assessed
using FreeSurfer v5.3, while volume changes were
assessed using Boundary Shift Integral (whole brain,
lateral ventricles) [56] and Tensor-Based Morphom-
etry (frontal and temporal lobes) [57].
Patients were monitored throughout the study for
adverse events, including use of clinical laboratory
tests (including measurement of methaemoglobin
by pulse CO-oximetry), physical and neurological
examinations, and 12-lead electrocardiograms (ECG)
at all clinic visits (screening, baseline, and weeks 2,
16, 32, 52, and 56). The Unified Parkinson’s Disease
Rating Scale Part III (UPDRS) [58] was included as
a motor safety outcome measure requested by a regu-
latory agency, as was the Columbia-Suicide Severity
Rating Scale (C-SSRS) [59], which were assessed
at all visits. Patients were also systematically moni-
tored for potential serotonin syndrome using a rating
scale derived from four published diagnostic criteria
[60], because of a theoretical potential for serotonin
syndrome [61]. By protocol, amyloid related imaging
abnormalities (ARIA), serotonin toxicity, and suici-
dality were to be reported as serious adverse events
for expedited reporting.
Statistical analysis
The primary analyses were conducted in the
Modified Intent-to-Treat (MITT) population (all ran-
domized patients who took at least one dose of study
drug and had both a Baseline and at least one post-
Baseline efficacy assessment; n = 214). The MRI
imaging population comprised all MITT population
patients with a Screening/Baseline and at least one
valid post-baseline volumetric assessment (n = 209).
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The primary analyses were specified as a mixed
model, repeated-measures analysis with an unstruc-
tured covariance matrix and no imputation for
missing data. The model included visit (three lev-
els corresponding to assessments at weeks 16, 32,
and 52), treatment group (two levels, 4 mg or 100 mg
twice a day), a visit by treatment group interaction
term, use of AD-labelled medications (two levels,
using or not using), geographic region (three levels:
North America, Asia/Australia, Europe), and base-
line value of the variable analyzed. The individual
comparisons were implemented through contrasts.
The Bonferroni-Holm correction was used to take
account of multiplicity arising from alternative co-
primary outcomes (FAQ and whole brain atrophy).
We used the same method for all secondary analyses
in predefined gated sequences such that no further
adjustment of alpha (0.05) was needed.
A sensitivity analysis was conducted to compare
baseline MRI scans with those available from the
parallel study in mild AD (TRx-237-005) [44] using
the Statistical Parametric Mapping (SPM12) software
package (http://www.fil.ion.ucl.ac.uk/spm/)) in anal-
yses controlled for age, sex, and total intracranial
volume.
Safety analyses were based on the Safety Popu-
lation comprising 218 patients who received at least
one dose of study drug, with summaries presented
according to dose.
Data analyses specified in the Statistical Analysis
Plan were undertaken independently of the fun-
der by SynteractHCR (Carlsbad, CA, USA) using
SAS 9.4 (Enterprise Guide v7.1). The results were
verified and additional exploratory analyses were
provided by two of the co-authors (HS, BOS) using R
version 3.3.0 (2016-05-03). Additional voxel-based
morphometric analyses (VBM) were provided by VV,
TA, and RTS using the SPM12 software package.
This trial is registered at http://www.clinicaltrials.gov
(NCT01626378) and the European Union Clinical
Trials Registry (EudraCT 2011-005529-34).
Population PK analysis
Blood samples for assessment of parent MT, N-
desmethyl MT, and total MT (sum of parent MT
and a labile LMT conjugate), were collected from
each patient on the first treatment visit (two sam-
ples: pre-dose and approximately 3.5 h after the dose)
and at each subsequent on-treatment visit. The pro-
tocol specified that PK plasma sampling was to
be conducted only at sites with adequate facilities
(i.e., a refrigerated centrifuge and adequate capabil-
ity to freeze samples reliably). Blinded analyses were
conducted at the University of Aberdeen GLP Test
Facility. MT levels in plasma were measured using
liquid chromatography-tandem mass spectrometry
assay. The method was validated for use in the Phase
III studies over the range 0.2 to 10 ng/ml. Extrap-
olated MT concentrations were available below the
lower limit of quantitation (but above the lower
limit of detection) in approximately 35% of the
Day 1 patients randomized to the 8 mg/day dose.
Model development and estimation of steady state
maximum plasma concentration (Cmax,ss) were deter-
mined independently by the Institute of Clinical
Pharmacodynamics (ICPD, NY, USA). Cmax,ss esti-
mates using a model validated in Phase I studies
were based on in-clinic plasma concentration data
obtained on Day 1 when the dose-sampling interval
was accurately recorded. The percentage of patients
with Day 1 exposure levels below the lower calibra-
tion limit of the assay was used to define a proxy
for placebo in post-hoc binary statistical compar-
isons of patients with low and high exposure to
the drug with a view to informing the design of
a future placebo-controlled trial. Change in ACE-
R, ACE-III, FAQ, MMSE, Modified-CGIC, FRS,
whole brain volume (WBV), lateral ventricular vol-
ume (LVV), and frontotemporal volume (FTV), as
well as UPDRS Part III, were expressed as a func-
tion of Cmax,ss estimates grouped into four groups
described in the results section. Cmax,ss values outside
3x the interquartile range were excluded from deter-
mination of concentration-response relationships, but
were included in inferential statistical analyses.
The concentration-response analyses used a
Mixed-effect Model Repeat Measurement (MMRM)
with per-subject correction and an unstructured
covariance matrix according to the following for-
mula:
Treatment effect∼ plasma-level x visit + plasma-
level x co-medication-status + co-medication-status x
visit + MMSE-class x visit + sex x visit + age-class x
visit + geographical-region + baseline-score
The following terms were categorical variables in
the models used for concentration-response analy-
ses: plasma level (five levels), visit (three levels),
co-medication status with AD drugs (two levels),
geographical-region (three levels),MMSE-class (two
levels, ≤20 and >21), and age-class (two levels, ≤65
and ≥66). For the longitudinal analyses, plasma level
was described by two levels (above or below thresh-
old). The sex x visit andage x visit terms were included
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because of the significant differences in baseline
severity between males and females and the likely
influence of age given that the age range of patients
in this study was wide (42–79 years). Since severity
was shown to be a significant parameter in the primary
ACE-R and FAQ analyses, severity as determined by
MMSE score was used as a rate term in the model
as MMSE-class x visit. There were too few cases tak-
ing LMTM in combination with AD-labelled drugs
in whom plasma concentration and efficacy data were
both available to permit separate analyses according
to co-medication status to be conducted. Pharmaco-
dynamic analyses were undertaken independently by
ICPD and were confirmed by HS and BOS.
A further analysis was undertaken (HS, BOS)
using a modified form of the Hill equation which
is commonly used in the analysis of concentration-
response data [62] in order to estimate the minimum
and maximum plasma concentrations for expected
treatment response over 52 weeks. The Hill
equation was applied under the assumption of non-
cooperativity and used imposed zero values where
the no-effect level was taken as -12 ACE-R units, 8
FAQ units or –30 cm3 for whole brain volume at a
Cmax,ss concentration of 0.29 ng/ml based on visual
inspection of the data. Use of different limiting
values did not meaningfully change the results. In
addition, a linear term was added to permit trends
occurring at high concentrations to be included in
the model. For decline in whole brain volume at this
dose, patients were split further into terciles to permit
estimation of the maximum limiting concentration
at which the treatment effect was lost. The mod-
ified Hill equation was applied to the data in the form:
change in parameter = Emin − (Emax x([C]−
0.29))/(EC50 + ([C] − 0.29)) + (A x ([C] − 0.29))
where Emin and Cmin are the imposed zero values,
where E is the mean treatment response for any
given Cmax,ss subgroup; Emax is the maximum
treatment effect as estimated from a standard Hill
equation without the additional linear term; EC50 is
the Cmax,ss at which the treatment effect is 50% of
the maximum response as estimated from a standard
Hill equation without the additional linear term;
A x (Cmax ,ss – Cmin ) is a further linear term in
which A is estimated by the model to take account
of the trends seen at high concentrations. In order to
relate Cmax,ss values to theoretical doses in a future
trial, a linear model was fitted to the mean plasma
concentrations at the 8, 150, 200, and 250 mg/day
doses using data from both AD patients, and 8
mg/day and 200 mg/day from bvFTD patients:
estimated dose = 22.22 x (Cmax ,ss – 0.016)
where dose is in mg/day and Cmax,ss is in ng/ml units.
Role of the funding source
The funder of the study (TauRx) took the lead in
study design, undertaking the study, data interpreta-
tion, and initial drafting of the report.
RESULTS
Study disposition and population characteristics
at baseline
The disposition of patients randomized to Study
007 is shown in Fig. 1.
Of 1,030 patients who were initially thought to be
suitable for inclusion in the trial by investigators, 810
(78.6%) were found to be ineligible either during pre-
liminary assessment prior to screening (661, 64.2%)
or at formal screening (149, 14.5%), with only 220
(21.4%) enrolled and randomized. Reasons relating
to diagnosis (clinical and MRI imaging) and severity
accounted for the majority exclusions (309, 30.0%).
Only 18 (1.7%) exclusions were due to meeting DSM
IV criteria for other psychiatric conditions, whereas
71 (6.6%) were due to other neurological disorders
and a further 81 (7.9%) were found not to meet cri-
teria for probable bvFTD, with the majority of these
excluded prior to formal screening. As expected, the
majority of medical exclusions (38 from a total of 47
[5.8%]) emerged only during formal screening. Oper-
ational reasons represented the second largest group
of exclusions overall (227, 28.0%), including unwill-
ingness to participate (86, 8.3%), inability to comply
with study procedures (64, 6.2%), and residence in
continuous care facility (26, 2.5%) as the largest cat-
egories. Overall, therefore, only 20% of patients that
investigators initially thought might be suitable met
the criteria for enrolment.
The demographic characteristics of the 220
patients randomized are summarized in Table 1.
Mean age was 63.3 years, ranging from 42 to 79
years, with more men (63%) than women (37%).
Patients were distributed geographically between
Europe (46%), North America (41%), and Aus-
tralia/Asia (13%).
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Fig. 1. Trial profile.
Table 1
Demographic characteristics of the randomized Intent to Treat Population
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Age (y)
Mean (SD) 63.1 (7.35) 63.6 (7.52) 63.3 (7.42)
Median (range) 63.0 (43–78) 64.0 (42–79) 63.0 (42–79)
n (%) <60 y 32 (28.8%) 27 (24.8%) 59 (26.8%)
n (%) ≥60 y 79 (71.2%) 82 (75.2%) 161 (73.2%)
Sex n (%)
Male 67 (60.4%) 71 (65.1%) 138 (62.7%)
Female 44 (39.6%) 38 (34.9%) 82 (37.3%)
Race n (%)
American Indian or Alaska Native 4 (3.6%) 4 (3.7%) 8 (3.6%)
Asian 4 (3.6%) 3 (2.8%) 7 (3.2%)
Black or African American 0 1 (0.9%) 1 (0.5%)
White 102 (91.9%) 99 (90.8%) 201 (91.4%)
Other 1 (0.9%) 2 (1.8%) 3 (1.4%)
Patients had been diagnosed with bvFTD for
almost 2 years on average (median, 1.1 years; rang-
ing up to 17.6 years). The mean MMSE (SD) at
baseline was 24.6 (3.1) with an almost equal distri-
bution of patients with a score of 22–26 (85 patients,
39%) and greater than 26 (81 patients, 37%). Females
were more impaired than males on the MMSE scale
(males 25.4 (3.5), females 22.9 (4.0), p < 0.001) and
ACE-R (males 72 (16), females 62 (14), p < 0.001)
scales, although not on the FAQ or FRS scales. Sever-
ity of frontotemporal atrophy was predominantly
Kipps stages 2 or 3 (82.3%) with 17.7% at Kipps
stage 4 [51] (Table 2). Baseline disease character-
istics were similar in distribution across treatment
groups, regions, and centers. Comparative summaries
of baseline biological characteristics of patients in
the present bvFTD study and the AD study popu-
lations reported previously [44, 45] are provided in
Supplementary Tables 1–3.
Co-medication utilization is summarized in
Table 3. Approximately one-fifth of all patients (21%
overall) were receiving an AChEI and/or memantine
therapy at screening, while almost half (46%) were
using medical food or alternative pharmacotherapy.
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Table 2
Clinical characteristics of patients at baseline
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Years since bvFTD diagnosis
n 107 106 213
Mean (SD) 1.9 (2.4) 1.9 (2.4) 1.9 (2.4)
Median (range) 0.9 (0.0–14.9) 1.1 (0.0–17.6) 1.1 (0.0–17.6)
MMSE score
Mean (SD) 24.6 (3.1) 24.7 (3.0) 24.6 (3.1)
≤21 28 (25.2%) 26 (23.9%) 54 (24.5%)
22–26 46 (41.4%) 39 (35.8%) 85 (38.6%)
>26 37 (33.3%) 44 (40.4%) 81 (36.8%)
Kipps stage, n (%)
2 38 (34.2%) 42 (38.5%) 80 (36.4%)
3 55 (49.5%) 46 (42.2%) 101 (45.9%)
4 18 (16.2%) 21 (19.3%) 39 (17.7%)
Table 3
Co-medication status of patients in study
Characteristic Hydromethylthionine Hydromethylthionine Total
8 mg/day 200 mg/day
(n = 111) (n = 109)
Use of AChEI/memantine (Concomitant medication) n (%)
AChEI and/or memantine 25 (22.5%) 20 (18.3%) 45 (20.5%)
Both AChEI and memantine 7 (6.3%) 3 (2.8%) 10 (4.5%)
AChEI only 10 (9.0%) 7 (6.4%) 17 (7.7%)
Memantine only 8 (7.2%) 10 (9.2%) 18 (8.2%)
Use of Medical Food or Alternative Pharmacotherapy for Dementia n (%)
Yes 54 (48.6%) 49 (45.0%) 103 (46.8%)
No 57 (51.4%) 60 (55.0%) 117 (53.2%)
Use of Selective Serotonin Reuptake Inhibitor (SSRI) n (%)
Yes 30 (27.0%) 33 (30.3%) 63 (28.6%)
No 81 (73.0%) 76 (69.7%) 157 (71.4%)
Use of Drugs of Serotonergic Potential n (%)
Yes 49 (44.1%) 62 (56.9%) 111 (50.5%)
No 62 (55.9%) 47 (43.1%) 109 (49.5%)
Fig. 2. Voxel-based morphometric comparison showing regions
of greater atrophy (yellow) in patients with bvFTD compared to
AD patients with mild AD (n = 713), from study TRx-237-005,
controlled for age, sex, and total intracranial volume of each indi-
vidual. Blue color indicates greater atrophy in AD patients. Data
are displayed at a significance threshold corrected for family-wise
error at the whole brain level at p < 0.05.
Antidepressant serotonergic reuptake inhibitors were
used by 29%, and drugs with potential serotonergic
activity were taken by 50%.
Validation of diagnosis and genetic mutations
Since patients in this study were recruited from 70
trial sites in 13 countries (not necessarily from FTD
specialist centers), we sought to determine the extent
to which patients meeting consensus clinical criteria
[1] and the further requirement for evidence of defi-
nite frontal and/or temporal lobe atrophy on MRI scan
[51] were distinct from mild AD. This was examined
by using VBM to compare the distribution of brain
atrophy in patients in this study with those enrolled in
a parallel study of mild AD (TRx-237-005) in which
similar MRI procedures were used. This comparison
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is shown in Fig. 2. bvFTD patients in this study had
significantly more atrophy in frontal cortex and ante-
rior temporal cortex, and significantly less atrophy
in hippocampus, middle temporal gyrus, cuneus, and
insula. We have also reported recently that bvFTD
patients in this study had significantly more atrophy
in frontal cortex than the other lobes. This contrasts
with the AD group, which showed more distributed
patterns of atrophy and with more atrophy in tempo-
ral, parietal, and occipital lobes than the bvFTD group
[63]. The MRI differentiation between bvFTD and
AD patients is consistent with the high degree of con-
fidence of a clinical diagnosis of bvFTD previously
reported in a clinicopathological study [23].
Of 159 cases analyzed genetically, seven were
found to have mutations in coding regions for either
tau (6, 3.8%) or TDP-43 (1). This is similar to the
frequency previously reported for bvFTD patients
having tau mutations (3%) [23]. For the one case with
a TDP-43 mutation, the mutation was I383V. There
were four cases with a P301L mutation in the tau cod-
ing region, one with G272V, and one with R406W.
Treatment effects were not analyzed separately in
these cases.
Prespecified efficacy analyses
There were no significant differences on any of the
primary or secondary outcomes at 52 weeks between
patients receiving hydromethylthionine 200 mg/day
and those receiving 8 mg/day as randomized and as
prespecified in the Statistical Analysis Plan. These
results are shown in Table 4.
Analyses based on population PK data
Data for plasma concentration and time from tak-
ing the first dose were available for 171 patients out
of 220. Patients receiving hydromethylthionine at a
dose of 8 mg/day were split into four groups based on
Cmax,ss to provide an independent biological classi-
fication according to drug exposure at this dose. The
plasma concentration ranges used for this purpose
are as indicated in Table 5. The cut-off that defined
the upper limit of the lowest 35% group (correspond-
ing to the percentage of patients with plasma levels
below the validated limit of quantitation on Day 1; 32
patients) was 0.346 ng/ml. The remainder with Day 1
plasma levels within the validated calibration range of
the assay were distributed into terciles having approx-
imately 20 patients (22%) each. Small changes in the
group boundaries did not meaningfully change the
results. As expected, plasma levels in the 80 patients
receiving the 200 mg/day dose were 16-fold higher
than the highest level seen at 8 mg/day.
Concentration-response relationships are shown
(Fig. 3) for change in ACE-R, FAQ, WBV, and
FTV over 52 weeks for all patients in whom data
Table 4
Modeled difference in change from baseline for the respective endpoints comparing patients receiving hydromethylthionine 8 mg/day and
200 mg/day on primary and secondary outcomes. (UPDRS, although a safety outcome, is also included.)
Decline±SEM Difference±SEM CI p
for LMTM 8 mg/day from LMTM 8 mg/day
group (n = 110) for 200 mg/day (n = 104)
ACE-R –9.98 ± 1.39 –0.49 ± 2.10 –4.64, 3.66 0.8170
FAQ 5.51 ± 0.55 –0.39 ± 0.84 –2.05, 1.26 0.6410
WBV (cm3) –21.64 ± 1.56 –1.35 ± 2.32 –5.94, 3.23 0.5614
MMSE –3.41 ± 0.53 –0.12 ± 0.80 –1.69, 1.42 0.8836
CGIC –1.05 ± 0.11 –0.04 ± 0.16 –0.35, 0.28 0.8252
FRS –0.1240 ± 0.0136 0.0075 ± 0.0206 –0.0332, 0.0482 0.7176
ACE-III –10.70 ± 1.55 0.44 ± 2.27 –4.05, 4.93 0.8469
UPDRS – part III 3.90 ± 1.06 –1.40 ± 1.61 –4.59, 1.78 0.3850
Table 5
Plasma-modeled parent MT Cmax,ss for hydromethylthionine groups
Dose groups Cmax,ss (ng/ml)
n (%) Mean (SD) Range
8 mg/day
8 mg/day – Group 1 32 (35%) 0.321 (0.0198) 0.281–0.346
8 mg/day – Group 2 20 (22%) 0.355 (0.0082) 0.346–0.372
8 mg/day – Group 3 19 (21%) 0.387 (0.0121) 0.373–0.409
8 mg/day – Group 4 20 (22%) 0.470 (0.0537) 0.413–0.583
200 mg/day 80 9.040 (1.6259) 6.800–14.235
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Fig. 3. Model-derived least square mean and standard error estimates of change of 52 weeks for clinical (a, b) and MRI volumetric endpoints
(c, d) according to plasma concentration groups (8 mg/day) or dose (200 mg/day).
Table 6
Binary pharmacological activity analysis based on a plasma parent MT threshold of 0.346 ng/ml to define a proxy for placebo; modelled
difference in change from baseline for the respective endpoints
All patients Patients receiving
hydromethylthionine 8 mg/day
Decline ± Difference ± CI p Nlow Nhigh Difference ± CI p Nlow Nhigh
SEM for Cmax,ss SEM for Cmax,ss SEM for Cmax,ss
≤ 0.346 ng/ml > 0.346 ng/ml > 0.346 ng/ml
ACE-R –11.33 ± 2.09 1.37 ± 2.60 –3.73, 6.47 0.5973 30 130 5.06 ± 2.62 –0.08, 10.21 0.0536 30 60
FAQ 7.13 ± 1.06 –2.98 ± 1.10 –5.15, –0.82 0.0069 30 129 –3.27 ± 1.32 –5.85, –0.69 0.0131 30 60
WBV (cm3) –27.72 ± 2.73 9.05 ± 3.06 3.06, 15.04 0.0031 28 115 11.67 ± 3.41 5.00, 18.36 0.0006 28 52
LVV (cm3) 9.13 ± 0.82 –3.41±–0.95 –5.27, –1.55 0.0003 28 107 –4.12 ± 1.06 –6.19, –2.05 <0.0001 28 46
FTV (cm3) –2.47 ± 0.22 0.73 ± 0.24 0.26, 1.19 0.0023 28 115 0.72 ± 0.27 0.19, 1.26 0.0076 28 52
FRS –0.14 ± 0.03 0.04 ± 0.03 –0.02, 0.10 0.1527 30 130 0.04 ± 0.03 –0.03, 0.10 0.2519 30 60
CGIC –1.34 ± 0.20 0.42 ± 0.22 –0.02, 0.85 0.0623 30 130 0.64 ± 0.27 0.12, 1.17 0.0157 30 60
MMSE –2.95 ± 0.93 –0.43 ± 1.05 –2.48, 1.62 0.6788 30 130 0.41 ± 1.04 –1.64, 2.45 0.6974 29 58
ACE-III –9.47 ± 2.40 1.27 ± 2.73 –4.08, 6.61 0.6418 26 122 4.36 ± 2.94 –1.40, 10.13 0.1380 29 58
UPDRS-part III 5.71 ± 1.85 –3.27 ± 2.09 –7.37, 0.81 0.1163 29 123 –4.31 ± 2.69 –9.58, 0.95 0.1085 31 62
were available for estimated Cmax,ss of parent MT in
plasma.
As can be seen, there are steep concentration-
response relationships for plasma levels in the range
0.3–0.6 ng/ml at the 8 mg/day dose on clinical and
MRI outcomes. The patients with plasma Cmax,ss lev-
els less than 0.346 ng/ml have worse outcomes than
those with levels above this threshold at the 8 mg/day
dose. At substantially higher plasma concentrations,
in the range 6.8–14.2 ng/ml seen in patients receiv-
ing the 200 mg/day dose, treatment effects are also
generally worse.
In order to inform a future confirmatory study,
binary outcome analyses were performed in which
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Fig. 4. Model-derived least square mean and standard error estimates of change of 52 weeks for clinical (a, b, c, d) and MRI volumetric
endpoints (e, f) in patients taking hydromethylthionine 8 mg/day categorized by plasma levels above or below the Cmax,ss threshold of
0.346 ng/ml.
the group of patients with minimal systemic expo-
sure to the drug was used as a proxy for placebo.
These are shown in Table 6 and illustrated in Fig. 4.
Compared to patients with subthreshold plasma
concentrations, patients with plasma Cmax,ss above
the 0.346 ng/ml threshold at the 8 mg/day dose have
significantly better outcomes on FAQ, Modified-
CGIC, WBV, LVV, and FTV, and near-significant
differences on ACE-R and UPDRS. There are no
exposure-dependent differences in MMSE or FRS.
Treatment differences are generally larger for com-
parisons restricted to patients receiving the 8 mg/day
dose. This is due to inclusion of patients receiving
the 200 mg/day dose who have worse outcomes than
patients with above-threshold plasma levels at the
8 mg/day dose.
In order to understand the exposure-response rela-
tionship better, the data were explored further using
an expanded version of the Hill equation [62]. This
provided a robust fit to the mean concentration-
response for change in ACE-R, FAQ, and WBV over
52 weeks (Fig. 5). The model fit for these outcomes is
consistent with the assumption that the lower limiting
plasma concentration required for treatment response
is 0.29 ng/ml in patients receiving the 8 mg/day dose.
The whole brain volume data in patients receiving the
200 mg/day dose were sufficiently homogeneous to
permit further subgrouping into terciles (Fig. 5). This
made it possible to derive an estimate of the upper
limiting concentration (13.6 ng/ml, corresponding to
a theoretical dose of 301 mg/day) at which the treat-
ment effect would be lost (Fig. 5).
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Fig. 5. Expanded Hill equation analysis of pharmacological activ-
ity of hydromethylthionine on change in ACE-R, FAQ, and WBV
using model-derived least squares mean and standard error esti-
mates of change over 52 weeks for clinical (a,b) and MRI
volumetric (c) endpoints according to plasma concentration group
(8 mg/day) or dose (200 mg/day). Scales at the top of each panel
indicate actual doses or calculated theoretical intermediate doses.
Using data from the combined AD and bvFTD
populations, we have reported previously that a dose
of 16 mg/day would be sufficient to ensure that
all patients have plasma levels above the threshold
required for pharmacological activity [49]. However,
the Hill equation analyses suggests that pharmaco-
logical activity is predicted to peak in the vicinity
of a 30 mg/day dose (Fig. 5). At this dose, the treat-
ment effect on the FAQ scale is predicted to be 7.73
[CI 5.50, 12.81] units (mean and confidence inter-
val based on bootstrap analysis), and the treatment
effect on whole brain atrophy is predicted to be
18.52 cm3 [CI 14.29 cm3, 23.70 cm3]. A simulation
of the plasma concentration profile for 30 mg/day,
given as single daily dose, is shown in the Supple-
mentary Figure 1.
Safety outcomes
The safety evaluation was based on the 218 patients
who enrolled in this study and took at least one dose of
hydromethylthionine (Safety Population). Of the 218
patients in the Safety Population, 110 (50.5%) were
randomized to 8 mg/day and 108 (49.5%) were ran-
domized to 200 mg/day. The compliance was high,
97% for 8 mg/day and 94% for 200 mg/day patients
meeting a criterion defined as between 80% and
120% of planned doses based on tablet returns. The
8 mg/day dose was better tolerated, with a withdrawal
rate of 15% over 12 months compared with 38% for
the 200 mg/day dose.
Treatment emergent adverse events (TEAEs) were
reported by 88 (80%) patients in the 8 mg/day group
and 103 (95.4%) patients in the 200 mg/day group.
TEAEs were judged by the Investigator to be related
to study drug in 30% of patients in the 8 mg/day group
and 56% of patients taking 200 mg/day. The major-
ity of TEAEs were mild to moderate in intensity.
A summary of TEAEs with an incidence of ≥5%
of patients in any treatment group is provided in
Table 7. TEAEs that showed an increase in incidence
with hydromethylthionine 200 mg/day relative to
8 mg/day include anemia, diarrhea, dysuria, nausea,
pollakiuria, insomnia, and vomiting. Renal and uri-
nary disorders were reported with greater frequency
in patients receiving hydromethylthionine 8 mg/day
with above-threshold plasma levels (26%) compared
with those with below-threshold levels (18%). At
least one severe TEAE was reported in 13 (12%)
hydromethylthionine 8 mg/day patients and 17 (16%)
in 200 mg/day patients. More patients (35 [32%])
treated with hydromethylthionine 200 mg/day expe-
rienced a TEAE resulting in a dose reduction,
interruption, or withdrawal of study drug as com-
pared to patients treated with hydromethylthionine
8 mg/day (15 [14%]). The UPDRS was included to
ensure there was no adverse effect on motor func-
tion. Patients did not have evidence of impaired motor
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Table 7
Number (%) of patients with at least one TEAE with an incidence of ≥5% of patients in any treatment group – Safety Population
MedDRA System Organ Hydromethylthionine Hydromethylthionine
Class/Preferred Term 8 mg/day (n = 110) 200 mg/day (n = 108)
Patients Reporting at Least One Adverse Event 88 (80.0%) 103 (95.4%)
Gastrointestinal disorders 28 (25.5%) 42 (38.9%)
Diarrhea 9 (8.2%) 24 (22.2%)
Vomiting 5 (4.5%) 9 (8.3%)
Infections and infestations 38 (34.5%) 34 (31.5%)
Nasopharyngitis 8 (7.3%) 7 (6.5%)
Urinary tract infection 13 (11.8%) 14 (13.0%)
Injury, poisoning and procedural complications 18 (16.4%) 16 (14.8%)
Fall 10 (9.1%) 13 (12.0%)
Investigations 17 (15.5%) 34 (31.5%)
Blood folate decreased 6 (5.5%) 9 (8.3%)
White blood cells urine positive 1 (0.9%) 6 (5.6%)
Metabolism and nutrition disorders 12 (10.9%) 14 (13.0%)
Folate deficiency 2 (1.8%) 6 (5.6%)
Nervous system disorders 33 (30.5%) 27 (25.0%)
Headache 8 (7.3%) 5 (4.6%)
Psychiatric disorders 29 (26.4%) 31 (28.7%)
Agitation 9 (8.2%) 9 (8.3%)
Insomnia 3 (2.7%) 7 (6.5%)
Renal and urinary disorders 25 (22.7%) 28 (25.9%)
Dysuria 0 6 (5.6%)
Pollakiuria 3 (2.7%) 10 (9.3%)
Urinary incontinence 13 (11.8%) 9 (8.3%)
Respiratory, thoracic and mediastinal disorders 12 (10.9%) 8 (7.4%)
Cough 7 (6.4%) 2 (1.9%)
function at the start of treatment and there was no
worsening over time.
Protocol-specified adverse events of special inter-
est included significant hematological findings
(methemoglobinemia, hemolytic anemia, presence
of Heinz bodies), serotonin syndrome, and ARIA.
The frequency of affirmative C-SSRS responses prior
to treatment was the same for both dosage groups
(8 mg/day, 7 (6.4%); 200 mg/day, 6 (5.6%)) and
remained unchanged following treatment. There was
one aborted suicide attempt in a patient who had
a prior history of an attempt that was not reported
as a TEAE and the patient continued with treat-
ment. There was 1 death among patients receiving
hydromethylthionine at the 8 mg/day dose, and 3 in
patients exposed to the 200 mg/day dose. None of
these events was judged by the investigator as being
related to treatment. Patients were closely monitored
for evidence of possible serotonin syndrome/toxicity
using a 20-item structured examination based on
published criteria [64, 65]. No subject had sero-
tonin syndrome reported as an AE. Three subjects
(2 randomized to 8 mg/day and 1 randomized to
200 mg/day) had myoclonus reported as an AE. How-
ever, none of these was considered by investigators
to be due to serotonin toxicity after clinical review.
DISCUSSION
We report the results of the largest therapeutic
trial conducted in bvFTD to date along with an
embedded population PK analysis. The study was
designed to compare a high dose of hydromethylth-
ionine (200 mg/day) with a low dose (8 mg/day)
intended as a control. As in two similarly designed
trials in AD [44, 45], there were no significant
differences between these two doses on any effi-
cacy outcome. In AD, we have reported recently
that there are steep concentration-response relation-
ships on cognitive and MRI outcomes for steady
state plasma levels in the range 0.3–0.8 ng/ml at
the 8 mg/day dose, and that plasma concentrations
in the range 4–21 ng/ml produced by doses in the
range 150–250 mg/day are not associated with any
additional benefit [49]. We now report a similar
exposure-response profile in bvFTD. There are steep
concentration-response relationships on clinical and
MRI outcomes for steady state plasma levels in the
range 0.3–0.6 ng/ml on the clinical ACE-R and FAQ
scales and whole brain atrophy measured by MRI.
High plasma concentrations, in the range 7–14 ng/ml
for subjects receiving the 200 mg/day dose, produce
worse outcomes.
514 H. Shiells et al. / Hydromethylthionine Reduces bvFTD Clinical Decline and Brain Atrophy
The exposure-response space we have now been
able to define permits a better understanding of
the relationship between dose and pharmacologi-
cal activity. The lack of dose-response comparing
hydromethylthionine at 8 mg/day with 200 mg/day
is due to two main factors. First, there is a steep
exposure-response relationship at the 8 mg/day dose
such that the majority of patients have blood levels
sufficient for pharmacological activity on clinical and
MRI volumetric outcomes. Second, there is a bipha-
sic response at concentrations substantially higher
than required for pharmacological activity such the
pharmacological activity at 200 mg/day is either no
greater or less compared with that seen in patients
with adequate blood levels at the 8 mg/day dose.
Modelling using an expanded version of the Hill
equation produced robust fits to the clinical and
MRI data. This analysis suggests that 0.29 ng/ml is
the minimum limiting plasma concentration of the
drug required for pharmacological activity, and that
13.6 ng/ml (corresponding to a theoretical dose of
301 mg/day) is the upper limiting concentration for
activity.
We have reported recently that variability in expo-
sure at the 8 mg/day dose is determined primarily
by renal function as measured by creatinine clear-
ance [49]. Patients with high creatinine clearance
have relatively lower steady state plasma levels of the
drug and vice versa. Since the bvFTD population is
younger and the mean creatinine clearance is higher, a
higher dose of hydromethylthionine may be required
than in AD. Whereas the predicted optimal dose for
treatment of AD is about 16 mg/day, we estimate that
a dose in the vicinity of 30 mg/day is required in
bvFTD. The Hill equation analysis suggests that a
broad range of doses (20–60 mg/day) are likely to
produce roughly comparable treatment effects and
would provide an adequate range for dosing flexi-
bility in clinical practice.
The doses of hydromethylthionine required for
pharmacological activity are substantially lower than
that previously identified for MTC in AD [47].
Hydromethylthionine has better brain delivery of
LMT than does MTC following oral dosing [31,
49]. This is due in part to 20-fold more efficient
uptake into red blood cells which is needed for
the drug to escape first-pass metabolism which
leads to loss of activity [26], and a correspond-
ing 60-fold or greater brain:plasma ratio compared
to MTC [49]. The plasma concentration threshold
of 0.346 ng/ml required for clinical pharmacologi-
cal activity in bvFTD is very close to that identified
in mild/moderate AD (Cmax,ss 0.373 ng/ml). Like-
wise, the non-linear concentration-response profile
is similar to that seen in AD [49], although the bipha-
sic response profile is more pronounced in bvFTD.
Both diseases are characterized by pathology of pro-
tein aggregation. The protein involved is TDP-43
in more than half of bvFTD cases, whereas in AD
it is tau protein in the majority of cases, with an
unknown contribution of cases with limbic TDP-43
pathology [66]. The estimated brain concentration
of hydromethylthionine required for pharmacologi-
cal activity (0.02–0.06M) [49] is consistent with
its activity as an inhibitor of both tau [27] and TDP-
43 [65] aggregation [34] in vitro, and with the doses
required for activity in a tau transgenic mouse model
of bvFTD [31]. In addition to different clinical man-
ifestations and response to symptomatic treatments,
the underlying pathology affects different classes of
brain cells with a different neuroanatomical distribu-
tion in AD and bvFTD [67–69]. It is therefore striking
that hydromethylthionine has similar pharmacologi-
cal activity with respect to clinical decline and brain
atrophy over similar concentration ranges of the drug
in two distinct neurodegenerative disorders.
In addition to effects on pathological protein aggre-
gation, the MT moiety has been reported to have
effects on dopamine and serotonin. Bhurtel and col-
leagues reported that MTC (given in the oxidized
MT+ form as MTC at a dose of 20 mg/kg intraperi-
toneally) restores dopamine levels in a mouse model
of Parkinson’s disease using 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) [70]. MPTP is
not itself toxic, but produces toxicity in dopaminer-
gic neurons via a metabolite produced by monoamine
oxidase in the brain [71]. However, no effect was
seen when MTC was given alone, suggesting that
the primary mechanism is via an interaction with
monoamine oxidase. It has been reported that MT+
inhibits monoamine oxidase (IC50 5.5M; [72]) and
serotonin transporter (IC50 1.2M; [73]) activity in
vitro. Since the estimated brain concentrations of
hydromethylthionine required for clinical pharma-
cological activity in bvFTD are more than an order
of magnitude below these values it is unlikely that
the treatment effects seen clinically are mediated
by a direct effect on serotonin neurotransmission.
Using a tau transgenic mouse model, we have recently
reported that hydromethylthionine increases acetyl-
choline levels in the hippocampus and normalizes
glutamate release in synaptosomes prepared from
brain tissues at clinically relevant doses. It is there-
fore likely that, in addition to direct effects on protein
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aggregation pathology, there are secondary effects
in neurotransmitter systems compromised by pathol-
ogy.
We have used the results from this study to inform
the design of a planned placebo-controlled trial. For
this purpose, we defined a subthreshold patient group
with minimal drug exposure as a proxy for placebo.
The study was powered to detect a 50% reduction
in the expected annual decline over 52 weeks for
patients with definite evidence of fronto-temporal
atrophy estimated to be 13.4 ± 2.1 ACE-R units based
on an observational study [51]. The decline observed
in patients with minimal drug exposure as defined by
the 0.346 ng/ml threshold is 11.3 ± 2.1 ACE-R units,
and is therefore comparable, although a more recent
study in patients meeting only clinical diagnostic cri-
teria reported a smaller decline [4]. Other than the
Kipps et al. study [51], which included MRI evidence
of fronto-temporal atrophy to exclude phenocopies,
other available studies had only clinical requirements
using either the Neary et al. [74] or Rascovsky et al.
[1] criteria. In the comparisons which follow, we
have used the published data to calculate standard
errors for comparison. The annualized decline on
the FAQ scale was reported as 5.81 ± 1.11 units in
bvFTD [21], 5.6 to 8.8 units (extrapolated from 26-
week data in patients randomized to either placebo or
memantine [18]), and 3.73 ± 0.39 [75]. The decline
observed in patients with subthreshold plasma lev-
els was 7.13 ± 1.06 units. The ADCS-CGIC score
after 12 months was reported as 5.27 (SD 0.88)
[21], corresponding to a change score of –1.27 ± 1.11
units. The decline on the Modified-CGIC in patients
with subthreshold plasma levels was –1.34 ± 0.20
units. The annualized decline on the MMSE scale has
been reported as –2.45 ± 0.79 [21] and –3.98 ± 0.54
[75]. The MMSE decline observed in patients with
subthreshold plasma levels was –2.95 ± 0.93 units.
Finally, the decline in whole brain volume reported in
a bvFTD cohort was 20.8 cm3 [76]. The correspond-
ing decline in patients with subthreshold plasma
levels was 27.7 ± 2.7 cm3. Therefore, allowing for
differences in patient selection criteria, the decline
observed across multiple metrics in patients with min-
imal drug exposure is comparable to that reported
for patients in historical studies. Compared against
patients with subthreshold plasma levels, the treat-
ment differences for patients receiving 8 mg/day with
plasma levels above the 0.346 ng/ml threshold are
5.1 units (p = 0.0536, 45% reduction) on the ACE-R
scale, –3.3 units (p = 0.0131, 46% reduction) on the
FAQ scale, 0.64 Modified-CGIC units (p = 0.0157,
48% reduction), –4.3 UPDRS units (p = 0.0711, 75%
reduction) and 11.7 cm3 (p = 0.0006, 42% reduction)
in whole brain atrophy. These binary exposure-
dependent differences cannot be accounted for by
differences in severity, sex, age, co-medication status
with AD drugs, or geography since these variables are
corrected for in the concentration-response analysis
model.
There have been several proposals regarding selec-
tion of primary and secondary outcomes for studies in
bvFTD, based on historical observational data, the-
oretical treatment effect sizes and other theoretical
considerations [21, 75–78]. Unlike AD, where trial
methodology has evolved over a 40-year period and
a consensus has emerged as to the domains which
should be assessed as primary outcomes, there is no
general agreement as to the best ways to measure
treatment effects in bvFTD. In a recent review, 50
different primary and secondary outcome scales are
listed for clinical trials reported in bvFTD between
2003-2015 [78]. Based on the present results, FAQ
and Modified-CGIC appear to have the greatest
power as clinical outcomes in practice, consistent
with previous suggestions [75, 76], and change in
whole brain [76] or lateral ventricular volume have
the greatest power as supportive biomarker outcomes.
In contrast to AD, the functional outcome measure
(FAQ) performs better than the cognitive outcome
measures (ACE-R and ACE-III) we have used. It also
has greater clinical relevance and face validity [53].
An apparent effect on the UPDRS motor assessment
scale is surprising, although involvement of basal
regions early in the disease process has been reported
[79, 80].
The safety profile of hydromethylthionine seen in
the present study is very similar to that seen in the two
AD studies we have reported. Comparing 200 mg/day
with 8 mg/day, there is a dose-dependent increase in
adverse events recorded as anemia, dysuria, pollak-
iuria, diarrhea, nausea, insomnia, and vomiting. In
patients receiving the 8 mg/day dose, the higher fre-
quency of renal and urinary adverse events in patients
with above- versus below-threshold plasma levels
(26% versus 18%) is consistent with higher plasma
levels. At a dose of 8 mg/day, the safety profile is
generally benign. This dose is well tolerated, with a
withdrawal rate of 15% over 12 months, compared
with 38% for the 200 mg/day dose.
There are important limitations in the inferences
which can be drawn from the present study. A post-
hoc exposure-response analysis of the kind we have
undertaken does not prove efficacy. It provides a
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means of determining how pharmacological activ-
ity is related to plasma concentration, and hence
dose. However, pharmacological activity is not the
same thing as efficacy. Efficacy can be established
only by demonstrating a statistically significant effect
on prespecified outcomes in a suitable randomized
placebo-controlled trial. The analyses presented here
are hypothesis generating and serve the purpose of
informing the design of a confirmatory placebo-
controlled trial which is now planned. The group
sizes in the analyses comparing exposure-dependent
differences at the 8 mg/day dose are small (46–62
with high exposure against 28–31 with low exposure),
although comparable with other studies conducted in
bvFTD [14–19]. The fact that there are consistent
exposure-dependent differences achieving nominal
significance on a range of clinical and MRI outcomes
based on relatively small numbers of subjects sug-
gests that the effects, if confirmed, are likely to be
clinically meaningful.
Conclusion
We report the results of the largest clinical trial
in bvFTD to have been conducted to date, combined
with a population PK analysis in 80% of the par-
ticipating patients in whom drug concentration and
efficacy outcome data were available. The random-
ized comparisons between hydromethylthionine at
a dose of 200 mg/day and a low dose of 8 mg/day,
thought to be inactive, did not show any difference
on the intended primary or secondary outcomes.
However, the population PK analyses conducted
post-hoc imply that 8 mg/day produces significantly
better outcomes in patients with adequate exposure
to the drug compared to those with minimal expo-
sure at the same dose. Hydromethylthionine shows a
biphasic concentration-response profile such that the
high plasma levels associated with the 200 mg/day
dose produce worse outcomes. In patients with
adequate systemic exposure at the 8 mg/day dose,
hydromethylthione has pharmacological activity with
respect to clinical decline and brain atrophy, reducing
decline by almost half compared with patients with
minimal drug exposure. If confirmed in a further trial,
these would represent potentially meaningful clinical
gains in a severely debilitating condition for which no
effective treatment options exist at present. The sim-
ilarity in the concentration-response profiles at the
8 mg/day dose in AD and bvFTD is consistent with
a common molecular mechanism of action linked
to inhibition of pathological protein aggregation. A
placebo-controlled trial in bvFTD aiming to deter-
mine whether hydromethylthionine is efficacious in
bvFTD is now planned.
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